[Correspondence] Drug-coated balloon angioplasty and stenting for coronary artery lesions – Authors' reply

We deeply appreciate the feedback provided by Tingquan Zhou, Pitt O Lim, Christian Spaulding and colleagues, Filippo Luca Gurgoglione and Bernardo Cortese, and Tuomas T Rissanen and colleagues. Introduced by Scheller and colleagues1 in 2004, drug-coated balloon (DCB) angioplasty has emerged as an attractive alternative to stent-based interventions. Studies and consensus documents have supported the application of DCBs in de novo small-vessel disease;2,3 nevertheless, a pertinent question remains regarding the applicability of DCB in de novo lesions across all vessel diameters.